Kornimate/medical-research-clean huggingface dataset:
method - bone marrow derived mononuclear cells in chronic ischemic disease

Conditions: Chronic Ischemic Heart Disease

Summary: intramyocardial, noga guided injection of bone marrow derived mononuclear cells in patients with chronic ischemic heart disease and lvef \< 40%. the primary objective is to determine whether the administration of the cells improves recovery of the left ventricular function. secondary objective is the finding of clinical or paraclinical parameters to predict potential benefits of the treatment (basing on mri characteristics such as size, transmurality of the myocardial infarction and peri-lesional ischemia). in the first part of the study 10 patients are treated without control group. this phase serves as feasibility and safety part of the study.


Eligibility criteria:
inclusion criteria: * chronic cardiac ischemic disease at least 4 months after one ore more myocardial infarctions in a stable phase of the disease without option for revascularization * lvef at echocardiography ≤ 40% * significant regional lv wall motion dysfunction in the infarct related territory * symptoms nyha ii-iv or ccs ii-iii (at least class iii according to one of the two classifications) * patient agrees to comply with all follow-up evaluations * age \> 18 years old * patient has been informed of the nature of the clinical trial and agrees to its provision and has provided written informed consent exclusion criteria: * abnormal regional wall motion outside the infarct region * need for revascularization in a non infarct-related coronary within 6 months * patient has moderate to severe aortic valve disease, aortic or mitral prosthetic valve * patient has a significant mitral valve insufficiency (effective regurgitant office - ero - \> 0.2 cm2 with possibility of mitral valve surgery * left ventricular thrombus at echocardiography * lv-aneurysma planned surgical aneurysmectomy * lv-wall thickness \< 5mm in the target territory * congenital heart disorder of hemodynamic relevance * known active infection or chronic infection with hiv, hbv or hcv * chronic inflammatory disease * serious concomitant disease with a life expectancy of less than one year * follow up impossible (no fixed abode, etc) * contraindication for cardiac mri (i.e. pace maker, neurostimulator, claustrophobia) * severe renal failure (creatinine \> 250 mmol/l) * relevant liver disease (got \> 2x norm or spontaneous inr \> 1,5) * anemia (hb \< 8.5 mg/dl), thrombocytopenia (\< 100.000/µl) * women of child bearing potential or pregnancy * participation at a clinical trial in the last 30 days

Keywords: lvef < 40%
developmental outcomes of extreme prematurity, 5-15 years postpartum

Conditions: Preterm Infants; Post Traumatic Stress Disorder; Emotional Stress; Infant, Very Low Birth Weight

Summary: the purpose of this study is to assess the emotional well being of mothers to preterm infants with elbw 5-15 years after the birth. post-traumatic symptoms and parental stress levels will be taken into consideration. in addition, the correlation between the infant's development and the mother's emotional state will be analyzed.

medical records of the children will be used for information in four categories: prenatal, birth, development,and demographic information. parents will be contacted and interviewed regarding the child's development. in addition, they will complete the following questionnaires: ppq-ii perinatal ptsd questionnaire- modified, ptgi -the posttraumatic growth inventory,parental stress index- short form- psi-sf, and life events questionnaire.

Eligibility criteria:
inclusion criteria: * preterm infant * very low birth weight or extremely low birth weight exclusion criteria: * missing information regarding birth week and weight

Keywords: ptsd preterm premature vlbw
positive association of us-fli with the severity of cad

Conditions: Coronary Artery Disease of Significant Bypass Graft; Metabolic Dysfunction-associated Fatty Liver Disease; SYNTAX Score; Ultrasonography

Summary: as a multisystem disease, metabolic dysfunction-associated fatty liver disease (mafld) is closely linked to the onset and progression of coronary heart disease (chd). ultrasonographic fatty liver indicator (us-fli) is a semi-quantitative tool for evaluating the degree of hepatic steatosis. our study aims to explore the relationship between us-fli based on mafld and the severity of chd.

204 patients who had invasive coronary angiography performed between july 2022 and december 2023 at the cardiology department of the second affiliated hospital of chongqing medical university were included in this study. collect clinical information and abdominal ultrasound images from each patient. hepatic steatosis which quantified by us-fli was evaluated by the echo contrast between liver and kidney, posterior attenuation of ultrasound beam, areas of focal sparing, display of hepatic vessels, gallbladder wall and diaphragm. fatty liver was diagnosed when us-fli≥2. the severity of chd was evaluated using the syntax score (ss), and a total of 100 chd patients were ultimately diagnosed. chd patients were further divided into the low-risk group (ss ≤ 22) (54 cases) and the medium-high-risk group (ss≥23) (46 cases). multivariate logistic regression model was used to assess the relationship between us-fli and ss in patients with mafld. the receiver operating characteristic curve was used to determine the accuracy, sensitivity and specificity of us-fli in predicting ss.

Eligibility criteria:
inclusion criteria: * patients older than 18 years old * patients underwent ica due to chest pain, chest tightness or other reasons in our hospital from august 2022 to december 2023 were included in our study exclusion criteria: * incomplete clinical data * previous coronary stent implantation * no abdominal ultrasound examination * poor ultrasound image quality * congenital heart disease * tumor * thyroid diseases and infectious diseases

Keywords: coronary artery disease metabolic dysfunction-associated fatty liver disease syntax score ultrasonography
a phase ii, open-label study evaluating the effect of gw786034 in subjects with ovarian cancer

Conditions: Peritoneal Cancer; Ovarian Cancer; Neoplasms, Ovarian; Fallopian Tube Cancer

Summary: this study was designed to find out how effective and safe gw786034, is in the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer that has not responded to standard treatment.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of epithelial ovarian, fallopian tube or primary peritoneal carcinoma. * has received one prior platinum-based chemotherapy regimen(cisplatin,carboplatin, or oxaliplatin). * has psychological, familial, sociological or geographical condition that does not permit compliance with the protocol. * is on a specifically prohibited medication or requires these medications during treatment with gw786034. exclusion criteria: * has had any surgery, chemotherapy, hormonal therapy, biologic, immunotherapy, or radiotherapy with in the last 28 days and has not recovered from such prior therapy. * poorly controlled hypertension(systolic 140mmhg or higher or diastolic 90mmhg or higher). * currently taking warfarin. * low molecular weight heparin and low-dose warfarin(1mg per day)is permitted.

Keywords: pazopanib fallopian tube cancer ovarian epithelial cancer peritoneal cancer
stereotactic image-guided navigation during breast reconstruction in patients with breast cancer

Conditions: Ductal Breast Carcinoma in Situ; Lobular Breast Carcinoma in Situ; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer

Summary: many hospitals, including the ohio state university medical center, will take pictures of the blood vessels in a patient's abdomen before they decide to perform a breast reconstruction using the patient's own tissue. these pictures are called computed tomography (ct) angiograms and are like a map of each patient's anatomy. however, no study has been reported that determined how accurate these pictures are at showing the surgeon where all of the blood vessels were located. this study will try to determine if these pictures are missing any blood vessels that are found during surgery and if the pictures show the correct location of the vessels

primary objectives: i. to analyze the accuracy of preoperative ct angiography in determining the location of perforator vessels. through the use of an intraoperative navigation system, we will objectively locate perforators during surgery and compare the results to the preoperative imaging assessment of the flap's vascular anatomy. ii. to determine whether the preoperative ct angiogram allows the microsurgeon to correctly identify the perforators that are ultimately used as the pedicle for the flap. outline: patients undergo deep inferior epigastric perforator (diep) flap breast reconstruction using the stealthstation navigation system. after completion of study treatment, patients are followed up at 1-2 weeks and 1 month, then every 3 months for 2 years.

Eligibility criteria:
inclusion criteria: * patients with histologically confirmed breast carcinoma or breast carcinoma in situ desiring unilateral or bilateral deep inferior epigastric perforator (diep) flap breast reconstruction * patients must be candidates for elective surgery, without clinically significant cardiac or pulmonary disease (new york heart association \[nyha\] class iii/iv), without infection requiring antibiotics, and without serious illness requiring the use of steroids * patients must have normal kidney function and no allergy to intravenous (iv) dye exclusion criteria: * patients with previous abdominal donor site flaps will be excluded along with patients with previous extensive surgery to the anterior abdomen * patients with a weight of over 300 pounds or a body size not supported by the ct scanner will be excluded * patients who are expected to undergo postoperative radiation therapy will be excluded
prospective german very high cardiovascular risk patients dyslipidemia treatment indication registry

Conditions: Dyslipoproteinemias; Hypercholesterolemia, Familial; Familial Hypercholesterolemia - Homozygous; Familial Combined Hyperlipidemia

Summary: this is a prospective german registry for patients with dyslipidemia with very high cardiovascular risk who principally meet the gemeinsamer bundesausschuss (g-ba) stipulations for proprotein convertase subtilisin/kexin like type 9 inhibitor (pcsk9i) use, and are treated by office-based cardiologists or in lipid ambulances.

the study is purely observational, and will document data from the patient charts only. treatment of patients will not be changed by this study, and all clinical decisions (including on frequency of visits) will be upon the discretion of the physician. no blood samples must be taken solely for the purpose of the study. the registry will include two types of centers: 1) office-based cardiologists and 2) specialized lipid ambulances (outpatient departments). data on patient disease and treatment history will be collected a first documentation (retrospectively). the documentation time is 3 years per patient. after the baseline visit, patients are followed-up every 6 ± 2months (last visit at month 36). this interval is considered narrow enough not to miss important events (safety reporting, cardiovascular events, hospitalizations). patients with stable (maintenance) lipid-lowering therapy (including those with existing pcsk9i therapy) or those with any therapy changes (including newly initiated pcsk9i treatment) will be documented in this study. compared to the former group with stable drug treatment, the latter group will likely have major ldl-c changes during the first few weeks, which will be accounted for by (retrospective) monthly documentation in the first 3 months (data will be documented at the 6-month visit. the documentation periods will be substantially longer than in the controlled studies of the pcsk9i (endpoints were as early as 3 months), and thus will provide much-needed information about the long-term effects on ldl-c and other lipid parameters, safety, and drug retention rates. longer follow-up periods would likely be compromised by high rates of (administrative) discontinuation rates.

Eligibility criteria:
inclusion criteria: * • with familial, homozygous hypercholesterolemia, in whom pharmaceutical and diet options for lipid lowering have proved insufficient, or * with confirmed familial, heterozygous hypercholesterolemia under consideration of the total familial risk, or * with heterozygous familial or non- familial hypercholesterolemia or mixed dyslipidemia with * therapy refractory course * maximal dietary and pharmaceutical lipid lowering therapy - in any case documented over a 12-month period * unsatisfactorily lowered ldl-c value (and thus with an indication for ldl apheresis) * confirmed vascular disease * other risk factors for cardiovascular events exclusion criteria: * concurrent participation of the patient in a clinical randomised study.

Keywords: cardiovascular ldl cholesterol drug utlisation high risk secondary prevention pcsk9 inhibition
effect of endodontic treatment on inflammatory markers, disease activity and periapical healing in rheumatoid arthritis patients with apical periodontitis : a prospective interventional study

Conditions: Rheumatoid Arthritis AND Apical Periodontitis

Summary: summary title: "effect of endodontic treatment on inflammatory markers, disease activity and periapical healing in rheumatoid arthritis patients with apical periodontitis" rationale: chronic inflammation plays a pivotal role in rheumatoid arthritis as subjects present with elevated serum levels of numerous cytokines such as il-1, il-6, 1l-12, il-17, tumour necrosis factor-alpha, rank and rank ligand. periodontal and pulpal inflammation are two major low grade chronic inflammatory diseases of the oral cavity. apical periodontitis extends from the chronic inflammatory process that originated in the dental pulp to surround the apex of the tooth. thus rheumatoid arthritis and apical periodontitis converge upon common pathway of inflammation. the scientific literature has also shown to provide potential link between endodontic infection and rheumatoid arthritis. the evidence of increased prevalence of apical periodontitis in subjects of rheumatoid arthritis is provided mainly by cross-sectional and case control studies. interventional studies have been performed in subjects with rheumatoid arthritis and periodontal disease, with results depicting beneficial effect of periodontal therapy in patients of rheumatoid arthritis. to best of our knowledge no interventional study has been performed to assess the healing pattern of apical periodontitis in subjects of rheumatoid arthritis and subsequently effect of endodontic intervention on inflammatory profile and disease burden in the same.


Eligibility criteria:
inclusion criteria: * 1. age of patients 30-65 years 2.definite diagnosis of rheumatoid arthritis based on acr/eular 2010 criteria\[28\] i.e a score of 6 or greater out of 10 from the individual scores in four domains: number and site of involved joints (range 0-5), serological abnormality (range 0-3), elevated acute-phase response (range 0-1) and symptom duration (two levels; range 0-1) 3. the periapical index (pai) will be used to evaluate the periapical status patients with pai \>or=3 as given by orstavik\[29\] will be included 4. presence of total teeth \>/= 12 exclusion criteria: 1. patients with periodontitis, pocket depth and cal\>5mm (stage 3, 4) will be excluded. 2. pregnancy; lactation \& contraceptives 3. patients with any other systemic disease other than rheumatoid arthritis i.e diabetes, hiv, chronic liver disease, chronic kidney disease and cardiovascular disease 5. conditions known to alter systemic inflammatory markers i.e orthopaedic trauma, surgery and viral infections 6. patients with bmi \>/= 30 7. medications (during last 3 months) known to affect systemic inflammatory markers (systemic steroids, immunosuppressants, hormone replacement therapy, contraceptives and systemic antibiotics) 8. smoking -
multi-modality imaging in peritoneal carcinomatosis of colorectal origin

Conditions: Peritoneal Carcinomatosis; Colorectal Cancer; Carcinoma; Neoplasms; Gastrointestinal Cancer

Summary: intraoperative tumor localization and resection can be enhanced using intraoperative fluorescence imaging and radiodetection. labetuzumab specifically recognizes cea which is is expressed on \> 95% of colorectal cancers.. therefore indium-111-dota-labetuzumab-irdye800cw is a perfect dual-labeled antibody for dual-modality image-guided surgery in peritoneal carcinomatosis of colorectal cancer.

in oncologic surgery complete tumor resection is important for treatment outcome and patient survival. when performing cytoreductive surgery (crs) for peritoneal carcinomatosis of colorectal origin it can sometimes be difficult to distinguish tumor deposits from adhesions and scar tissue. intraoperative tumor localization and resection can be enhanced using intraoperative imaging techniques (e.g. targeted radioguided or fluorescence guided surgery). a powerful synergy can be achieved by combining radiotracers (e.g. indium-111) and optical tracers (e.g. irdye 800cw) conjugated to an antibody against a tumor-associated antigen. labetuzumab specifically recognises cea which is expressed on \> 95% of all colorectal cancers. therefore indium-111-dota-labetuzumab-irdye800cw is a perfect dual-labeled antibody for dual-modality image-guided surgery in peritoneal carcinomatosis of colorectal origin. the concept has been shown in preclinical studies with mice and the investigators will translate this to the clinic. eligible patients with peritoneal carcinomatosis of colorectal origin scheduled for crs + hipec will receive dual-labeled labetuzumab 6-7 days before surgery. at day 4 or 5 a spect/ct of the abdomen and thorax will be obtained. cytoreductive surgery at day 7 will be extended with the use of a near-infrared fluorescence camera and a gamma probe. the aim of this study is to assess the feasibility and safety of intraoperative dual-modality imaging with indium-111-dota-labetuzumab-irdye800cw in peritoneal carcinomatosis of colorectal cancer.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of peritoneal carcinomatosis of colorectal origin * scheduled for cytoreductive surgery and hipec. * age over 18 years * signed informed consent exclusion criteria: * any medical condition present that in the opinion of the investigator will affect patients clinicals status * administration of a radionuclide within 10 physical half-lives prior to study enrollment * pregnancy or lactation * patients with very high (\>500ng/ml serum cea levels * known cea negative tumor

Keywords: image guided surgery crs hipec fluorescence antibodies, monoclonal
theratogs versus reciprocal electrical stimulation on children with diplegic cerebral palsy: a randomized controlled trial

Conditions: Down Syndrome

Summary: children with diplegic cerebral palsy exhibit postural restrictions as a result of both primary and secondary brain damage impairments. one of the main goals of cerebral palsy rehabilitation is to improve balance and stability. as a result, the purpose of this study is to compare the effects of theratogs and reciprocal electrical stimulation on postural stability in children with diplegic cp.


Eligibility criteria:
inclusion criteria: * diplegic children of both sexes are between the ages of 8 and 12. the level of spasticity in the lower limbs ranged from grade 1 to grade +1 on the modified ashworth scale (mas). the levels of motor function were between levels i and ii, according to the gross motor function classification system (gmfcs). exclusion criteria: * if they had no major medical issues, according to their medical report. skin diseases and allergic reactions to the adhesive tape used in this study were excluded, as were any deformities that interfered with lower limb functions, children with pace- makers who were contraindicated by electrical stimula- tion, children with visual, auditory, or perceptual deficits, and children with seizures.
assessment of family planning and immunization service integration in liberia

Conditions: Contraception; Contraceptive Usage; Contraception Behavior; Infant, Newborn, Diseases

Summary: this is a mixed methods process evaluation of a programmatic intervention to integrate family planning and immunization services at health facilities in lofa and grand bassa counties in liberia. mcsp used a longitudinal, pair-matched design to monitor the effect of integrating immunization and fp services on utilization of fp and routine immunization services. in lofa and grand bassa counties, 36 facilities were pair-matched to intervention and comparison sites based on predetermined criteria. after approximately 9 months of implementation, mcsp conducted a qualitative study employing key informant interviews (kiis) and focus group discussions (fgds) at intervention and comparison sites, and with district-, county-, and national-level moh supervisors and managers.


Eligibility criteria:
inclusion criteria: * 18 intervention facilities in lofa and grand bassa counties * 18 pair matched comparison facilities in lofa and grand bassa counties exclusion criteria: * facilities not included in the intervention or selected for pair matching